OpenFDA + PubChem + ClinicalTrials.gov Integration

FDA Detox Medications & Clinical Research Encyclopedia

Official US Food & Drug Administration (FDA) monographs, PubChem chemical pharmacology profiles, and active ClinicalTrials.gov research studies for addiction recovery and 24/7 medical detox.

FDA-Approved MAT & Detox Medications

Partial Opioid Agonist / MAT

Buprenorphine / Naloxone

FDA Approved (2002)

Brand Names: Suboxone, Zubsolv, Sublocade

FDA Indication:

Maintenance treatment of opioid dependence as part of a complete treatment plan including counseling and psychosocial support.

Receptor Mechanism: Partial agonist at the mu-opioid receptor and antagonist at the kappa-opioid receptor.

🚨 FDA Boxed Warning: WARNING: RISK OF SERIOUS HARM OR DEATH WITH ACCIDENTAL INGESTION; ADDICTION, ABUSE, AND MISUSE.

Package NDCs:54868-5256-012496-1208-10093-5720-56

OpenFDA API SynchronizedFind MAT Centers Offering Suboxone

Full Opioid Agonist / OTP

Methadone Hydrochloride

FDA Approved (1947)

Brand Names: Methadose, Dolophine

FDA Indication:

Detoxification treatment of opioid addiction and maintenance treatment of opioid dependence in certified Opioid Treatment Programs (OTP).

Receptor Mechanism: Full agonist at the mu-opioid receptor and NMDA receptor antagonist.

🚨 FDA Boxed Warning: WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; QT PROLONGATION.

Package NDCs:0054-3556-630054-4571-25

OpenFDA API SynchronizedFind MAT Centers Offering Methadose

Opioid Receptor Antagonist

Naltrexone Extended-Release

FDA Approved (1984 (Oral) / 2006 (Vivitrol Injectable))

Brand Names: Vivitrol, ReVia

FDA Indication:

Prevention of relapse to opioid dependence following opioid detoxification, and treatment of alcohol dependence.

Receptor Mechanism: Competitive antagonist at mu-opioid receptors, blocking euphoric effects of opioids and alcohol.

🚨 FDA Boxed Warning: WARNING: RISK OF HEPATOTOXICITY AT EXCESSIVE DOSES; OPIOID OVERDOSE RISK IF OPIOID BLOCK IS OVERRIDDEN.

Package NDCs:65757-300-010056-0079-01

OpenFDA API SynchronizedFind MAT Centers Offering Vivitrol

Opioid Antagonist / Emergency Reversal

Naloxone Hydrochloride

FDA Approved (1971 (FDA Over-The-Counter Approved 2023))

Brand Names: Narcan, Kloxxado, Zimhi

FDA Indication:

Emergency treatment of known or suspected opioid overdose, manifested by respiratory and/or central nervous system depression.

Receptor Mechanism: Pure opioid antagonist that competes for and displaces opioids at mu-opioid receptor sites.

Package NDCs:69547-353-0270518-2450-0

OpenFDA API SynchronizedFind MAT Centers Offering Narcan

GABA Modulator / Glutamate Receptor Antagonist

Acamprosate Calcium

FDA Approved (2004)

Brand Names: Campral

FDA Indication:

Maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation.

Receptor Mechanism: Restores glutamate and GABA balance in the central nervous system altered by chronic alcohol exposure.

Package NDCs:0456-3200-01

OpenFDA API SynchronizedFind MAT Centers Offering Campral

Alcohol Dehydrogenase Inhibitor / Aversion Agent

Disulfiram

FDA Approved (1951)

Brand Names: Antabuse

FDA Indication:

Aid in the management of selected recovery patients who want to remain in a state of enforced sobriety from alcohol.

Receptor Mechanism: Inhibits aldehyde dehydrogenase (ALDH), leading to toxic accumulation of acetaldehyde upon alcohol consumption.

🚨 FDA Boxed Warning: WARNING: DISULFIRAM SHOULD NEVER BE ADMINISTERED TO AN INDIVIDUAL WHEN THEY ARE IN A STATE OF ALCOHOL INTOXICATION.

Package NDCs:0054-0065-25

OpenFDA API SynchronizedFind MAT Centers Offering Antabuse

MAT & Detox Centers Geo-Map

FDA-Approved Medication Assisted Treatment (MAT) Centers

Balanced 50-State coverage with municipal pin markers across all US regions

Filter Municipality:

Active US Clinical Research Trials (ClinicalTrials.gov APIv2)

Live interventional studies currently recruiting patients for addiction and detox research

NCT05242965RECRUITING (PHASE2)

A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer

This phase II trial tests whether CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope plasmid DNA vaccine (STEMVAC) works to shrink tumors in patients with stage IV non-small cell lung cancer. STEMVAC targets specific immunogenic proteins that help lung cancer cells to grow. STEMVAC is made up of deoxyribonucleic acid (DNA), which is a natural substance in every living organism. DNA acts like a blueprint that tells all the cells in your body how to function. The DNA used in this study contains instructions for your body to produce parts of the 5 proteins the investigators identified (CDH3, CD105, YB-1, MDM2 and SOX2). STEMVAC is given with granulocyte-macrophage colony stimulating factor (GM-CSF) which is being used as an adjuvant to help create a stronger immune response. Giving STEMVAC with GM-CSF to patients while on maintenance therapy for non-small cell lung cancer (NSCLC) may help activate certain immune cells to recognize and kill lung cancer cells.

Sponsor: University of Washington

View Study on ClinicalTrials.gov

NCT06370481RECRUITING (NA)

HIV, Equity, and Addiction Training (HEAT) Program

This project is a pilot study to determine the feasibility and acceptability of a telemedicine intervention for substance use disorder service delivery in diverse people living with HIV in Alabama.

Sponsor: University of Alabama at Birmingham

View Study on ClinicalTrials.gov

NCT07592000RECRUITING (PHASE1)

Breakthrough - T1DM and Chronic Kidney Disease

Single arm- subject treated with Tegoprubart and everolimus. The purpose of this research is to gather information on the safety and effectiveness of investigational regimen containing 2 experimental components: * An investigational drug called Tegoprubart and * Human pancreatic islet cells Both Tegoprubart and human pancreatic islet cells are considered investigational because they are not approved for use in the United States by the Food and Drug Administration (FDA). Participation in this research will last about 5 years. Assess safety, tolerability, and efficacy of transplanted islet cells and immunomodulation with Tegoprubart in combination with anti-thymocyte globulin (ATG), etanercept and with everolimus in adults with brittle T1D and chronic kidney disease (stage 2-3a).

Sponsor: University of Chicago

View Study on ClinicalTrials.gov

NCT06553196RECRUITING (NA)

MATAspire: Mental Health Awareness Tailored App for Substance Prevention and Integrated Resilience Education

The MATAspire intervention is a web-app designed to promote substance misuse prevention education and bolster protective coping skills whereby students complete six weekly interactive modules using a smart device or computer. Each module is approximately 15-20 minutes long and focuses on select substances and coping strategies: (i) adaptive coping strategies, (ii) alcohol, (iii) cannabis, (iv) nicotine, (v) prescription drugs and opioids, (vi) final module. The modules are based on key theoretical constructs, behavior change strategies, and practical module components: attitudes (knowledge), perceived susceptibility (risk perceptions), and subjective norms (normative re-education). The intervention will be evaluated via a time series design using a sample of (\~1000 students) randomly assigned to either the intervention or the control conditions at a public institution in Southern California.

Sponsor: California State University, Northridge

View Study on ClinicalTrials.gov

50-State Geographic Directory